Document is current
Any future updates will be listed below
-
Authors
Amor, Melina
Bianco, Valentina
Buerger, Martin
Lechleitner, Margarete
Vujić, Nemanja
Dobrijević, Anja
Akhmetshina, Alena
Pirchheim, Anita
Schwarz, Birgit
Pessentheiner, Ariane R.
Baumgartner, Franziska
Rampitsch, Katharina
Schauer, Silvia
Klobučar, Iva
Degoricija, Vesna
Pregartner, Gudrun
Kummer, Daniel
Svecla, Monika
Sommer, Gerhard
Kolb, Dagmar
Holzapfel, Gerhard A.
Hoefler, Gerald
Frank, Saša
Norata, Giuseppe Danilo
Kratky, Dagmar
-
Funding
Funding for this research was provided by:
Austrian Science Fund (W1226, W1226)
Ministero della Salute (RF-2019-12370896)
Ministero dell’Università e della Ricerca (Progetto CN3-National Center for Gene Therapy and Drugs based on RNA Technology)
Medizinische Universität Graz (Flagship VascHealth)
Amt der Steiermärkischen Landesregierung (add-on funding SFB F73)
City of Graz (add-on funding SFB F73)
- License Information
-
More Information
Article History
Received: 6 September 2023
Accepted: 13 November 2023
First Online: 28 November 2023
Declarations
:
: All animal experiments were performed in accordance with the European Directive 2010/63/EU and approved by the Austrian Federal Ministry of Education, Science and Research (Vienna, Austria; BMBWF-66.010/0138-V/3b/2019). The study was conducted in accordance with the Declaration of Helsinki and approved by the ethics committees of the University Hospital Centre Sisters of Charity, Zagreb, Croatia (EP 13125/17 − 4; date of approval 7 September 2017), the University of Zagreb School of Medicine, Croatia, and the Medical University of Graz, Austria (31–532 ex 18/19; date of approval 17 September 2020).
: Written informed consent to participate in the study and publish results in medical journals was obtained from healthy volunteers and MS patients.
: The authors declare that no conflict of interest exists.
